BANGKOK (AP) – The Thai Prime Minister on Tuesday received footage of the AstraZeneca-made COVID-19 vaccine as much of Asia dismissed reports of blood clots in some recipients in Europe, saying there was no evidence yet. connect the two.
Many countries that use the vaccine say that the benefits of the vaccine outweigh the potential risks, even if parts of Europe discontinued it before considering possible side effects.
AstraZeneca has developed a production base in Asia, and the Indian Serum Institute, the world’s largest vaccine manufacturer, has contracted with the company to produce one billion doses of the vaccine for developing countries. Hundreds of millions more will be produced this year in Australia, Japan, Aponia, Thailand and South Korea.
“There are people who have concerns,” said Thai Prime Minister Prayut Chan-ochan after receiving the first dose of AstraZeneca vaccine. “But we have to trust the doctors, trust our medical professionals.”
Last week, Thailand was the first country outside Europe to temporarily suspend the AstraZeneca vaccine. Indonesia followed suit on Monday, saying it was awaiting a full report from the World Health Organization on possible side effects.
But Thai health officials decided to go ahead with AstraZeneca, and Pruitt’s cabinet received the first shots.
Many European countries, including Germany, France, Italy and Spain, stopped using the AstraZeneca vaccine on Monday due to rumors of blood clots in some recipients, although international regulators say there is no evidence the fire is to blame.
The EU Drug Enforcement Administration convened a meeting on Thursday to review experts’ findings on the AstraZeneca shooting to determine whether action was needed.
Other countries in the Asia-Pacific region have also said they will continue vaccination programs.
Philippine Presidential spokesman Harry Rocken said his country would not stop using it because the benefits outweighed the risks. Under the COVAX agreement of the World Health Organization, the country has so far received 525.00 doses of AstraZeneca vaccine, and so far has administered 12,788 doses. Several million more doses have been ordered by government: private companies.
“There is no clear evidence yet that AstraZeneca is the cause of the blood clot. “If such information is found out, we may also stop using AstraZeneca,” said Roken. “At this point, our experts are once again saying that the benefits we get from using AstraZeneca outweigh the side effects of this vaccine.”
Australian Health Minister Greg Hunt has said his country will not stop vaccinating. Australia has so far vaccinated about 200,000 people, plans to import from AstraZeneca and produce 70 million doses of the vaccine.
“The government clearly, unequivocally, fully supports the spread of AstraZeneca, clearly, unequivocally, absolutely. And the reason is very clear. “It will help save lives, save lives, it is done on the basis of medical advice,” Hunt told parliament.
Australia’s Chief Medical Officer Paul Kelly said there was no evidence that the vaccine caused blood clots.
“Blood clots happen, they happen quite often in Australia,” he said. “But from my point of view, I do not see any specific link between the AstraZeneca vaccine and the blood clots. I am not alone in that.”
The largest user of the AstraZeneca vaccine is India.
India uses two vaccines, AstraZeneca, shot by the Indian Serum Institute, and another vaccine, made by Bharat Biotech, India, to immunize its vast population. Of the more than 25.6 million people in India who have received the vaccine at least once, more than 23.4 million have received AstraZeneca shots, according to government figures.
Health officials told the Indian Press Trust on Saturday that a total of 234 adverse events, including 71 deaths, had been reported after receiving the vaccine, but no causal link had been found. The government is currently reviewing the cases for final evaluation.
India, the world’s largest vaccine institute in India, has partnered with AstraZeneca to develop a billion doses of vaccine for developing countries. According to the government, on March 4, India exported more than 48.1 million vaccines, including 11.9 million doses to COVAX և 28.8 million doses as a commercial export.
At the same time, health activists and health ethics experts in India have warned that India’s systems for monitoring harmful side effects are too weak.
With the exception of a few countries, such as Singapore and India, Asian countries are slow to vaccinate their populations. Most nations, including Australia, New Zealand, and Thailand, have been relatively successful in curbing the spread of COVID-19.
Thailand has ordered AstraZeneca և vaccinated China to cover about half of its population this year և and has so far vaccinated about 50,000 people at high risk.
Associated Press reporters in Bangkok: Chalida Ekvithayavechnukul, Man my Gomez in Manila, Rod McGurk in Canberra, Australia, Moussa Moussa in Sydney, Ninek Carmin in ak akarta, Indonesia in Noregos, Anirudeh K. Marie. Tokyo Yamaguchi contributed to this report